Patents Issued in December 20, 2018
  • METHODS AND COMPOSITIONS FOR DELIVERY OF MEDICAMENTS TO THE LUNGS
    Publication number: 20180360749
    Abstract: The disclosure provides a drug composition formulated for inhalation comprising a conjugate of a surface active agent and a pulmonary active drug. The surface active agent has an affinity for the human alveolar/gas interface and comprises at least a portion of a mammalian lung surfactant of a mimic thereof. The disclosure also provides a method of treating a subject suffering from or at risk of suffering from a lung disease comprising administering to the subject a conjugate comprising a drug for lung treatment and a surface active agent by inhalation in an amount effective to induce a drug effect in the lungs.
    Type: Application
    Filed: November 2, 2017
    Publication date: December 20, 2018
    Inventor: Frank Guarnieri
  • COMPOSITION FOR REDUCING MUSCLE CRAMPS
    Publication number: 20180360750
    Abstract: A composition for reducing muscle cramps includes a composition in a ratio by weight between 70% and 85% parts liquid water, between 3% and 7% parts sodium bicarbonate, and between 12% and 25% flavoring. The composition is drank to prevent muscle cramps.
    Type: Application
    Filed: June 16, 2017
    Publication date: December 20, 2018
    Inventor: Lillian Johnson
  • Transdermal cream for treating Dupuytren's Contracture
    Publication number: 20180360751
    Abstract: A pharmaceutically acceptable transdermal composition for the treatment of patients with musculoskeletal connective tissue fibrosis or a disorder including Dupuytren's Contracture, Peyronie's disease, Ledderhose disease, or Knuckle Pads, includes an active composition and a base composition. The active composition is present in the transdermal composition in an amount of about 10% to about 40% by weight of the transdermal composition and includes one or more growth factor antagonists. The base composition is present in an amount of about 60% to about 90% by weight of the transdermal composition and comprises a transdermal delivery system or transdermal carrier. A method of treating patients with musculoskeletal connective tissue fibrosis, including topically applying the transdermal composition in effective amount to the affected tissue is further disclosed.
    Type: Application
    Filed: June 15, 2018
    Publication date: December 20, 2018
    Applicant: Advanced Fibrosis Research LLC
    Inventors: Latha Satish, Carl Reese, Sandeep Kathju, Mark Baratz
  • TOPICAL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES
    Publication number: 20180360752
    Abstract: Topical pharmaceutical compositions and methods for treating a skin disease include tazarotene or a pharmaceutically acceptable salt of tazarotenic acid and an oil-in-water emulsion vehicle.
    Type: Application
    Filed: May 11, 2018
    Publication date: December 20, 2018
    Inventors: Angel Arturo, Pillai Radhakrishnan
  • A METHOD FOR PREPARATION OF REDUCIBLE DEGRADABLE HYPERBRANCHED POLYMERIC MICELLES
    Publication number: 20180360753
    Abstract: Provided are a reducible degradable hyperbranched-polymer nanomicelle and a method for preparation thereof and an application thereof. Cystamine and polyethylene glycol diglycidyl ether are polymerized by means of a nucleophilic addition mechanism; in one step, a hyperbranched polymer alternatingly arising from cystamine and polyethylene glycol structural units is synthesized and obtained; then, a hyperbranched nanomicelle is formed by means of self-assembly during the process of dialysis. The hyperbranched-polymer chain segments contain both tertiary aminos and disulfide bond structural units and have pH- and reduction responsiveness, and the hyperbranched three-dimensional cavity structure imparts a drug-carrying ability to the nanomicelle.
    Type: Application
    Filed: July 29, 2016
    Publication date: December 20, 2018
    Inventors: Caihua NI, Yamin ZHOU, Liping ZHANG, Gang SHI
  • COMPOSITIONS OF FLUOROCARBON NANOEMULSION, AND METHODS OF PREPARATION AND USE THEREOF
    Publication number: 20180360754
    Abstract: The invention provides novel compositions of fluorocarbon nanoemulsions comprising one or more of fluorosurfactants and phospholipids, and methods of preparation and use thereof for enhanced oxygen delivery.
    Type: Application
    Filed: December 20, 2016
    Publication date: December 20, 2018
    Inventors: Evan C. Unger, Edmund R. Marinelli
  • TARGET-SPECIFIC DELIVERY OF THERAPEUTIC AGENTS
    Publication number: 20180360755
    Abstract: Isolated peptides targeting cardiovascular disease are described herein or one or more conservative amino acid substitutions, deletions or additions of such peptides and methods of use thereof for delivering payloads to specific cell types or tissues.
    Type: Application
    Filed: June 15, 2016
    Publication date: December 20, 2018
    Inventors: Alexander L. Klibanov, Brent A. French, Kimberly A. Kelly, Siva Sai Krishna Dasa
  • Core/Shell Structure Platform For Immunotherapy
    Publication number: 20180360756
    Abstract: Disclosed are biocompatible core/shell compositions suitable for the delivery of populations of mRNA molecules to mammalian cells. The disclosed core-shell structured multicomponent compositions are optimized for the delivery of mRNAs encoding one or more cancer- or tumor-specific antigens to a population of antigen presenting cells, including, for example, human dendritic cells, macrophages and B cells. Also disclosed are methods for use of these compositions as therapeutic cancer vaccines.
    Type: Application
    Filed: January 26, 2018
    Publication date: December 20, 2018
    Inventor: Haifa SHEN
  • BIPHASIX CANNABINOID DELIVERY
    Publication number: 20180360757
    Abstract: A biphasix multilayered lipid vesicle cannabinoid composition comprising: (a) a first phase comprising a first oil-in-water emulsion; and (b) a second phase suspended in the first phase, the second phase comprising multilamellar lipid vesicles, the multilamellar lipid vesicles entrapping a second oil-in-water emulsion, wherein at least one of the first and second oil-in-water emulsions comprises a therapeutically effective amount of a cannabinoid. The composition for transdermal and topical administration for the treatment of pain.
    Type: Application
    Filed: May 25, 2018
    Publication date: December 20, 2018
    Inventors: Ahmad Doroudian, Patrick Frankham
  • NANOLIPOSOMES COMPRISING CORTICOSTEROID AS MEDICAMENTS AND METHODS TO PREPARE THEM
    Publication number: 20180360758
    Abstract: Nanoliposomes comprising at least one outer lipid bilayer and at least one corticosteroid encapsulated by the at least one lipid bilayer are provided. Uses of the nanoliposomes as a medicament and in the treatment of a cardiovascular disease are also provided. Further, methods of preparing the nanoliposomes are additionally provided.
    Type: Application
    Filed: November 28, 2016
    Publication date: December 20, 2018
    Inventors: Subramanian VENKATRAMAN, Jayaganesh V. NATARAJAN, Anastasia DARWITAN
  • Enzyme Delivery Systems and Methods of Preparation and Use
    Publication number: 20180360759
    Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 20, 2018
    Inventors: Joan M. Fallon, Matthew Heil
  • Methods For Administering Weight Loss Medications
    Publication number: 20180360760
    Abstract: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.
    Type: Application
    Filed: August 13, 2018
    Publication date: December 20, 2018
    Inventors: Anthony A. McKinney, Gary Tollefson, Eckard Weber, Rick Soltero
  • PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1
    Publication number: 20180360761
    Abstract: The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonaphthalen-1-yl)pyridine-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the “Agent”), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: December 7, 2016
    Publication date: December 20, 2018
    Applicants: Ardea Biosciences, Inc., AstraZeneca AB
    Inventors: Joanne REILAND WAKEMAN, Colin ROWLINGS, Sha LIU, Gerry BURKE, Christian VON CORSWANT, Christer TANNERGREN, Johan HJÄRTSTAM
  • BETA-LACTAMASE FORMULATIONS AND USES THEREOF
    Publication number: 20180360762
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Application
    Filed: August 24, 2018
    Publication date: December 20, 2018
    Inventors: Andrew Bristol, Michael Kaleko, Sheila Connelly
  • CONTROLLED RELEASE COMPOSITION AND METHOD
    Publication number: 20180360763
    Abstract: In one aspect, the present invention is directed to a method of making a controlled release solid dosage form having an ethylcellulose coating layer, which layer comprises a coalescing agent which is an organic ester having an HLB Value of from 3 to 8. The use of such coalescing agent permits the formation of an effective controlled release coating without the need for a further curing step after the coating process. In other aspects, this invention relates to an aqueous dispersion useful in such method; as well as to the coated dosage form produced.
    Type: Application
    Filed: August 3, 2018
    Publication date: December 20, 2018
    Inventors: HUI S. YANG, HUA MA, KEVIN STOKES
  • DELAYED SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS
    Publication number: 20180360764
    Abstract: Delayed sustained release pharmaceutical compositions that provide therapeutic effects over extended periods of time (i.e., 14-16 hours).
    Type: Application
    Filed: June 7, 2018
    Publication date: December 20, 2018
    Inventors: Tsz Chung LAI, Alexander Brian LIPPOLD, Rebecca Sue WALKER, Jae Han PARK
  • MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS
    Publication number: 20180360765
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Application
    Filed: August 22, 2018
    Publication date: December 20, 2018
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • OVARIAN CANCER SPECIFICALLY TARGETED BIODEGRADABLE AMPHIPHILIC POLYMER, POLYMER VESICLE PREPARED THEREBY AND USE THEREOF
    Publication number: 20180360766
    Abstract: Provided are an ovarian cancer specifically targeted biodegradable amphiphilic polymer, a polymer vesicle prepared thereby and use thereof. The biodegradable amphiphilic polymer is prepared by a polymer containing dithiocarbonate monomer bonded with targeting molecules. The polymer vesicle prepared with the biodegradable amphiphilic polymer can crosslink spontaneously without adding an extra crosslinker, and the crosslink has a reduction activity and hence can be used in drug controlled-release systems, and contributes to the clinical use and production of nano-drugs.
    Type: Application
    Filed: September 4, 2018
    Publication date: December 20, 2018
    Inventors: JIANDONG YUAN, FENGHUA MENG, YAN ZOU, ZHIYUAN ZHONG
  • BIOCOMPATIBLE PARTICLES AND METHODS OF MAKING AND USE THEREOF
    Publication number: 20180360767
    Abstract: Biocompatible particles comprising a metallic core and a plurality of drug-loading ligands coordinated to the metallic core are described. The metallic core can, for example, have a melting point of 100° C. or less. The biocompatible particles can, in some examples, further comprise a therapeutically effective amount of a drug coordinated to the plurality of drug-loading ligands. In some examples, the biocompatible particles can further comprise a plurality of targeting ligands coordinated to the metallic core. Also disclosed herein are methods of making the biocompatible particles described herein, for example using sonication. Also disclosed herein are methods of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of the biocompatible particles or compositions disclosed herein.
    Type: Application
    Filed: November 18, 2016
    Publication date: December 20, 2018
    Inventors: Zhen GU, Yue LU
  • MINERAL-BASED NANOPARTICLES FOR ARTHRITIS TREATMENT
    Publication number: 20180360768
    Abstract: Aspects of the invention are directed to mineral-based nanoparticles comprising silicate nanoparticles that induce human mesenchymal stem cells (hMSCs) into a cartilage-lineage through the upregulation of cartilage-specific genes resulting in the transformation of the cell phenotype into that of a chondrocyte, i.e., a cartilage producing cell. The silicate nanoparticles are synthesized through a process where the precipitate of sodium silicate is mixed with one or more elements and compounds and milled into nanoparticles.
    Type: Application
    Filed: December 21, 2016
    Publication date: December 20, 2018
    Inventors: Akhilesh K. Gaharwar, James K. Carrow
  • SYSTEMS AND METHODS FOR TRANSDERMAL DRUG DELIVERY
    Publication number: 20180360769
    Abstract: A liquid-reservoir system (LRS) for transdermal administration of (s)-ketorolac may include a backing layer that is substantially impermeable to (s)-ketorolac, isopropyl alcohol, isopropyl myristate, oleic acid, butylated hydroxytoluene, triethanolamine, hydroxypropyl cellulose, and water; it may additionally include an (s)-ketorolac reservoir layer including a liquid-reservoir gel formulation, a membrane layer, and a contact adhesive layer. The liquid-reservoir gel formulation may include: 1-15% by weight (s)-ketorolac or a salt thereof; one or more drug solubilizing vehicles; one or more permeation enhancers; an antioxidant; a thickening agent; purified water; and a buffering agent.
    Type: Application
    Filed: November 28, 2016
    Publication date: December 20, 2018
    Inventor: Samir ROY
  • Topical Formulation for Binding to Dermatological Cannabinoid Receptors
    Publication number: 20180360770
    Abstract: A topical cream or ointment is provided that provides for the binding to CB1 and/or CB2 receptors for the soothing of dermatological itching. The cream or ointment composition provides the effect of cannabinoids without the actual use of cannabinoids. Several essential oils, including Black Pepper, Ylang Ylang, and Melissa essential oils in combination, contain caryophyllene, a sesquiterpene, in effective amounts to bind to the CB2 receptor and help reduce an urge to itch the skin.
    Type: Application
    Filed: June 20, 2017
    Publication date: December 20, 2018
    Inventor: Jessica Kado
  • CANNABIDIOL CHEWING GUM
    Publication number: 20180360771
    Abstract: A cannabidiol chewing gum for delivering cannabidiol (CBD) to a user comprises one or more ingredients. The cannabidiol chewing gum comprises one or more of cannabidiol (CBD), gingerol, and caffeine. The user ingesting the cannabidiol chewing gum receives cannabidiol (CBD) from the cannabidiol chewing gum.
    Type: Application
    Filed: June 14, 2017
    Publication date: December 20, 2018
    Inventor: Yury Leon Shmerlis
  • Low-Temperature Inhalation Administration of Cannabinoid Entities
    Publication number: 20180360772
    Abstract: A cannabinoid material as active agent containing formulation comprising the active agent, an HFA propellant, and optionally a co-solvent is disclosed. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 50° C.
    Type: Application
    Filed: July 19, 2018
    Publication date: December 20, 2018
    Applicant: EP Pharma, LLC
    Inventors: Charles Raymond Eck, Christopher L. Pelloni
  • PROCESS FOR THE MANUFACTURE OF AJOENE DERIVATIVES
    Publication number: 20180360773
    Abstract: The present invention relates to the compound (E,Z)-ajoene of formula (1) for use in treatment of bacterial infections. Another aspect of the present invention is a composition comprising (E,Z)-ajoene of formula (1) and at least one antibiotic. Yet another aspect of the invention relates to a method for manufacturing (E,Z) ajoene of formula (1) wherein the conformation of the internal C?C— bond can be either E or Z or a mixture thereof, said method comprising reacting allicin of formula (3) with an acid in the presence of a solvent to provide (E,Z ajoene) of formula (1) as defined above. Yet another aspect of the invention is (E,Z)-ajoene of formula 1 obtainable by the method described above.
    Type: Application
    Filed: May 15, 2018
    Publication date: December 20, 2018
    Inventors: Thomas Bjarnsholt, Niels Høiby, Peter Østrup Jensen, Richard Phipps, Meenakshi Sundaram Shanmugham, Maria Alhede, Louise Dahl Hultqvist, Tim Holm Jakobsen, David Tanner, Thomas Ostenfeld Larsen, Michael Givskov
  • CURCUMIN-BASED COMPOSITIONS & METHODS OF USE THEREOF
    Publication number: 20180360774
    Abstract: Methods and compositions for increasing LDL receptor levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 15% curcumin II or at least 5% curcumin III, in order to increase LDL receptor levels. In addition, compositions for increasing LDL receptor levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 15% curcumin II or at least 5% curcumin III (or combinations of such curcuminoids), along with a pharmaceutically-acceptable solvent, filler, or carrier. Still further, methods and compositions for decreasing MSK1 levels in a plurality of cells are disclosed, which involve administering a curcumin III-enriched composition to the cells.
    Type: Application
    Filed: August 24, 2018
    Publication date: December 20, 2018
    Inventor: Franco Cavaleri
  • HISTONE DEACETYLASE INHIBITORS
    Publication number: 20180360775
    Abstract: Provided herein are compounds that act as histone deacetylase (HDAC) inhibitors, and can affect expression of genes in vivo and in vitro. These HDAC inhibitors are generally volatile compounds that can be administered as a gas or vapor. Such inhibitors can be used as therapeutics for numerous disease conditions, such as a variety of cancers, neural degenerative diseases, neurological diseases, senescence, and infectious diseases.
    Type: Application
    Filed: December 2, 2016
    Publication date: December 20, 2018
    Applicant: The Regents of the University of California
    Inventor: Anandasankar RAY
  • ANTI-OBESITY POTENTIAL OF GARCINOL
    Publication number: 20180360776
    Abstract: Disclosed are compositions containing garcinol for the therapeutic management of obesity. More specifically, the invention relates to the use of garcinol for a) maintaining energy balance in mammalian adipose cellular systems b) management of hypercholesterolemia and c) reducing weight gain in mammals. The modification of gut microbiota and the increase of beneficial microbe, Akkermansia muciniphila by garcinol are also disclosed.
    Type: Application
    Filed: June 13, 2018
    Publication date: December 20, 2018
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur
  • THERAPY FOR KINASE-DEPENDENT MALIGNANCIES
    Publication number: 20180360777
    Abstract: A pharmaceutically acceptable composition and method of therapy for a kinase-dependent malignancy in a patient in need of such therapy is provided. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of a tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for kinase-dependent malignancy. Also provided is a method to eradicate leukemia initiating cells (LIC) or cancer stem cells (CSC) in a patient being treated with a tyrosine kinase inhibitor.
    Type: Application
    Filed: February 20, 2018
    Publication date: December 20, 2018
    Inventors: Mohammad AZAM, Meenu KESARWANI
  • Compositions And Methods Useful For Treatment Of Respiratory Illness
    Publication number: 20180360778
    Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes.
    Type: Application
    Filed: August 23, 2018
    Publication date: December 20, 2018
    Inventors: Kelly Lee Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines
  • Compositions And Methods Useful For Treatment Of Respiratory Illness
    Publication number: 20180360779
    Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes.
    Type: Application
    Filed: August 23, 2018
    Publication date: December 20, 2018
    Inventors: Kelly Lee Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines
  • Compositions And Methods Useful For Treatment Of Respiratory Illness
    Publication number: 20180360780
    Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes.
    Type: Application
    Filed: August 23, 2018
    Publication date: December 20, 2018
    Inventors: Kelly Lee Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines
  • Compositions And Methods Useful For Treatment Of Respiratory Illness
    Publication number: 20180360781
    Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes.
    Type: Application
    Filed: August 23, 2018
    Publication date: December 20, 2018
    Inventors: Kelly Lee Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines
  • METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE
    Publication number: 20180360782
    Abstract: A method of modulating ribonucleotide reductase activity in a neoplastic cell includes administering to the cell an amount of a ribonucleotide reductase modulator (RRmod), the amount being effective to inhibit neoplastic cell growth.
    Type: Application
    Filed: December 9, 2016
    Publication date: December 20, 2018
    Inventor: Chris Dealwis
  • METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES
    Publication number: 20180360783
    Abstract: Disclosed herein is a method of prevention of progression of a multiple sclerosis in a patient, comprising the administration of methylglyoxal bis(guanylhydrazone) (MGBG) to the patient in need thereof. Also disclosed herein is a method of prevention or reduction in severity of the initiation phase of autoimmune response in a patient having multiple sclerosis, comprising the administration of MGBG to the patient in need thereof.
    Type: Application
    Filed: August 23, 2018
    Publication date: December 20, 2018
    Inventors: Jeremy BLITZER, John MCKEARN
  • X-RAY CONTRAST MEDIA COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT, REDUCE OR DELAY THE ONSET OF MIGRAINE
    Publication number: 20180360784
    Abstract: Embodiments disclosed herein relate to improved X-ray contrast media compositions and methods of using the same for treating symptoms related to allergic reactions, inflammatory conditions, symptoms of the common cold and certain cancers.
    Type: Application
    Filed: August 22, 2018
    Publication date: December 20, 2018
    Inventor: Elliott C. LASSER
  • THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS
    Publication number: 20180360785
    Abstract: Compositions and methods for the treatment of Charcot-Marie-Tooth disease and related disorders. Also provided are combination therapies for treating this disease by decreasing PMP22 expression in a subject.
    Type: Application
    Filed: August 6, 2018
    Publication date: December 20, 2018
    Inventors: Daniel Cohen, Ilya Chumakov, Oxana Guerassimenko, Serguei Nabirochkin
  • (R)-CARBIDOPA ALONE OR IN COMBINATION WITH A STEROID FOR TREATING PAIN, INFLAMMATION, AN INFLAMMATORY DISEASE, AN IMMUNE OR AUTOIMMUNE DISEASE AND TUMOUR GROWTH
    Publication number: 20180360786
    Abstract: The present invention relates to (R)-carbidopa and pharmaceutical compositions thereof, and to a combined preparation of (R)-carbidopa and a steroid, and to the use of the same in the treatment or prevention of medical conditions such as pain, inflammatory diseases, immune or autoimmune disorders and tumour growth.
    Type: Application
    Filed: December 7, 2016
    Publication date: December 20, 2018
    Applicant: PROXIMAGEN GROUP LIMITED
    Inventors: Martyn PRITCHARD, Peter RICHARDSON
  • METHODS AND COMPOSITIONS FOR TREATMENT FOR CORONARY AND ARTERIAL ANEURYSMAL SUBARACHNOID HEMORRHAGE
    Publication number: 20180360787
    Abstract: Methods and compositions for treating a complication associated with aneurysmal subarachnoid hemorrhage (SAH), the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof. Methods and compositions for treating vasospasm, the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof.
    Type: Application
    Filed: April 17, 2018
    Publication date: December 20, 2018
    Inventors: Marshall L. SUMMAR, Frederick E. BARR, Reid Carleton THOMPSON
  • Compositions And Methods For Treating Intestinal Hyperpermeability
    Publication number: 20180360788
    Abstract: The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (IBD), graft versus host disease (GVHD), HIV/AIDS, multiple organ dysfunction syndrome, irritable bowel syndrome (IBS), celiac disease, eczema, psoriasis, acute pancreatitis, Parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.
    Type: Application
    Filed: August 27, 2018
    Publication date: December 20, 2018
    Inventor: Steven Hoffman
  • NUTRITIONAL COMPOSITION AND INFANT FORMULA FOR PROMOTING MYELINATION OF THE BRAIN
    Publication number: 20180360789
    Abstract: A synthetic nutritional composition comprising a fatty acid derivative for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.
    Type: Application
    Filed: December 13, 2016
    Publication date: December 20, 2018
    Inventors: Nora Schneider, Jonas Hauser, Sean Deoni, Tamas Bartfai
  • NUTRITIONAL COMPOSITIONS AND INFANT FORMULAS TO PROMOTE MYELINATION IN THE BRAIN
    Publication number: 20180360790
    Abstract: The invention relates to a nutritional connposition for infants and young children, such as an infant formula or follow-on formula or growing up milk, preferably an infant formula, and comprising choline. The choline promotes and/or supports an ideal myelination trajectory in the brain, such trajectory being close to that observed in infants fed exclusively with human breast milk (HBM). The infants or young children can be between 0 and 60 months, preferably between 0 and 12 months of age.
    Type: Application
    Filed: December 13, 2016
    Publication date: December 20, 2018
    Inventors: Nora Schneider, Sean Deoni
  • FATTY ACID MONOGLYCERIDE COMPOSITIONS
    Publication number: 20180360791
    Abstract: The present invention relates to a method of treating a fungal condition caused by T. rubrum, by administering a composition comprising a fatty acid monoester of glycerol. According to an embodiment, the fatty acid monoester of glycerol is 1-monocaprin.
    Type: Application
    Filed: February 22, 2018
    Publication date: December 20, 2018
    Inventors: Jon D. LENN, Hans Hofland, Barry Thomas Hunt, Edward Hsia
  • Method of Treatment of Alopecia with Monoterpenoids
    Publication number: 20180360792
    Abstract: The present application generally relates to topical formulations comprising monoterpenoid compounds which are effective inhibitors of FGF-5-dependent signaling in hair follicles or parts thereof, the manufacture of such topical formulations, and their use to reduce, delay or prevent loss of terminal hair caused by FGF-5 signaling in the hair follicle, such as in subjects suffering from, or having a propensity to develop, alopecia.
    Type: Application
    Filed: July 19, 2018
    Publication date: December 20, 2018
    Inventors: Masakuni Yamamoto, Masato Namekata, Koichi Yamauchi, Takeo Matsumoto, Darren Ross Jones, Maria Halasz
  • HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS
    Publication number: 20180360793
    Abstract: The present application in one aspect provide Fc-containing polypeptide conjugates comprising an Fc-containing polypeptide conjugated to a conjugate moiety, wherein the Fc-containing polypeptide comprises an N-glycosylated Fc region comprising an acceptor glutamine residue flanked by an N-glycosylation site and wherein the conjugate moiety is conjugated to the Fc-containing polypeptide via the acceptor glutamine residue. Also provided are methods of making such Fc-containing polypeptide conjugates by using a wildtype or engineered transglutaminases. Further provided are engineered transglutaminases specifically designed for carrying out such reactions.
    Type: Application
    Filed: May 22, 2018
    Publication date: December 20, 2018
    Inventors: Sean HU, Lisha ALLEN
  • HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS
    Publication number: 20180360794
    Abstract: The present application in one aspect provide Fc-containing polypeptide conjugates comprising an Fc-containing polypeptide conjugated to a conjugate moiety, wherein the Fc-containing polypeptide comprises an N-glycosylated Fc region comprising an acceptor glutamine residue flanked by an N-glycosylation site and wherein the conjugate moiety is conjugated to the Fc-containing polypeptide via the acceptor glutamine residue. Also provided are methods of making such Fc-containing polypeptide conjugates by using a wildtype or engineered transglutaminases. Further provided are engineered transglutaminases specifically designed for carrying out such reactions.
    Type: Application
    Filed: May 22, 2018
    Publication date: December 20, 2018
    Inventors: Sean Hu, Lisha Allen
  • FUMIGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME
    Publication number: 20180360795
    Abstract: The disclosure provides fumagillol type compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided.
    Type: Application
    Filed: January 12, 2018
    Publication date: December 20, 2018
    Inventors: Robert Zahler, James E. Vath
  • Anavex2-73 for the Treatment of Alzheimer's Disease
    Publication number: 20180360796
    Abstract: Composition and method for treatment of Alzheimer's disease that includes ANAVEX2-73. Method of treatment of Alzheimer's disease using pharmaceutical compositions comprising ANAVEX2-73 according to an intermittent dosage regimen.
    Type: Application
    Filed: June 14, 2017
    Publication date: December 20, 2018
    Inventor: Marco Cecchi
  • TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM
    Publication number: 20180360797
    Abstract: The present invention relates to the treatment or prevention of tinnitus. More precisely, the present invention relates to a compound modulating chloride co-transporter NKCC1 (chloride co-transporter modulator) for use in the treatment of tinnitus. In addition, the present invention concerns pharmaceutical compositions comprising such an NKCC1 chloride co-transporter modulator as an active agent, a method for the treatment or prevention of tinnitus by administering such a chloride co-transporter modulator, an a screening method for the identification and characterization of compounds capable of modulating chloride co-transporter NKCC1.
    Type: Application
    Filed: January 12, 2018
    Publication date: December 20, 2018
    Inventors: Marlies KNIPPER-BREER, Luckas RUETTIGER
  • Lipid Furan, Pyrrole, and Thiophene Compounds for Treatment of Cancer, Neurological Disorders, and Fibrotic Disorders
    Publication number: 20180360798
    Abstract: Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective amount of a compound of Formula I, II, or III, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from a cancer, neurological disorder, or fibrotic disorder.
    Type: Application
    Filed: August 23, 2018
    Publication date: December 20, 2018
    Applicant: Avoscience, LLC
    Inventor: Richard Huber